High Prevalence and Incidence of Fractures in Patients Treated for Aggressive B-Cell Non-Hodgkin Lymphomas

Li‐Wen Huang(University of California, San Francisco), Charalambos Andreadis(University of California, San Francisco), Lawrence D. Kaplan(UCSF Helen Diller Family Comprehensive Cancer Center), Weiyun Z. Ai(City College of San Francisco), Dong Sun(University of California, San Francisco), Thomas Lang�(University of Vienna), Thomas M. Link(University of California, San Francisco)
Blood
December 7, 2017
10.1182/blood.v130.suppl_1.4131.4131
Cited by 0

Related Papers

Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|683
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523
In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
|Journal of Clinical Oncology|2010|487